Isolated femoral agenesis/hypoplasia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1987Q72.4
Who is this for?
Show terms as
11Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Isolated femoral agenesis/hypoplasia (also known as isolated proximal femoral focal deficiency or isolated femoral deficiency) is a rare congenital limb malformation characterized by the partial or complete absence (agenesis) or underdevelopment (hypoplasia) of the femur (thighbone). The condition may affect one leg (unilateral) or both legs (bilateral), with unilateral involvement being more common. The term 'isolated' indicates that the femoral deficiency occurs without other major associated anomalies, distinguishing it from syndromic forms such as femoral hypoplasia–unusual facies syndrome. Clinically, affected individuals present with significant limb length discrepancy, shortened thigh, and abnormal hip and knee joint mechanics. The degree of severity varies widely, ranging from mild shortening of the femur to near-complete absence of the bone. Associated findings may include hip instability, limited range of motion, abnormal gait, and functional impairment of the affected limb. The condition is apparent at birth and is often detected prenatally through ultrasound imaging. Management is multidisciplinary and depends on the severity of the deficiency and the degree of limb length discrepancy. Treatment options include orthotic devices, prosthetic fitting, limb lengthening procedures (such as distraction osteogenesis using external fixators), and reconstructive surgical interventions. In severe cases, rotationplasty (Van Nes rotation) or amputation followed by prosthetic rehabilitation may be considered to optimize function and mobility. Physical therapy and rehabilitation play an essential role throughout the patient's growth and development. The etiology of isolated femoral agenesis/hypoplasia remains largely unknown in most cases, and it typically occurs sporadically without a clear genetic cause.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors

First Affiliated Hospital of Zhejiang University — NA

TrialNOT YET RECRUITING
Feb 2026Evaluation of Internal Nasal Splint-Supported Free Graft Versus Nasoseptal Flap for Endoscopic Skull Base Repair in Cerebrospinal Fluid Leaks

Kafrelsheikh University — NA

TrialRECRUITING
Dec 2025Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia

Beijing 302 Hospital — PHASE1

TrialRECRUITING
Aug 2025NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery

Maria Sklodowska-Curie National Research Institute of Oncology — NA

TrialRECRUITING
Aug 2025Cefazolin Antibiotic Prophylaxis in Ventricular Shunt Surgery: Determination of Cerebrospinal Fluid Concentration During Valve Implantation

University Hospital, Strasbourg, France — NA

TrialNOT YET RECRUITING
Jul 2025Multiomics Profiling of CSF in Cardiac Arrest Survivors

Chungnam National University Hospital

TrialACTIVE NOT RECRUITING
Jul 2025Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

Yeon Hee Park — PHASE2

TrialRECRUITING
May 2025Assessment of CSF Shunt Flow and Headaches With a Thermal Measurement Device

Rhaeos, Inc. — NA

TrialRECRUITING
Apr 2025Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein

University of Freiburg — NA

TrialRECRUITING
Jan 2025VentricuLostomy AssoCiaTed InfeCtions (LACTIC): Focus on CSF Lactate and Sampling Site

Rigshospitalet, Denmark

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Isolated femoral agenesis/hypoplasia.

View clinical trials →

No actively recruiting trials found for Isolated femoral agenesis/hypoplasia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Isolated femoral agenesis/hypoplasia community →

Specialists

11 foundView all specialists →
RP
Richard Kocharian, MD, PhD
Specialist
PI on 3 active trials
AS
Anthony Shields
Specialist
PI on 2 active trials10 Isolated femoral agenesis/hypoplasia publications
FM
F. Stephen Hodi, MD
Specialist
PI on 5 active trials
SM
Scot C. Remick, MD
SCARBOROUGH, ME
Specialist
PI on 9 active trials
SM
Siv Fonnes, MD
Specialist
PI on 2 active trials
RD
Robert J Amato, DO
Specialist
PI on 4 active trials6 Isolated femoral agenesis/hypoplasia publications
CM
Craig L. Slingluff, MD
CHARLOTTESVILLE, VA
Specialist
PI on 5 active trials
LZ
Longjiang Zhang
Specialist
PI on 1 active trial
SM
Saeed Mirsadraee
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Isolated femoral agenesis/hypoplasia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Isolated femoral agenesis/hypoplasiaForum →

No community posts yet. Be the first to share your experience with Isolated femoral agenesis/hypoplasia.

Start the conversation →

Latest news about Isolated femoral agenesis/hypoplasia

Disease timeline:

New recruiting trial: Cardiac Hemodynamics During Left Ventricular Assist

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: New CSF Biomarkers for Alzheimer's Disease

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: OH2 Injection in Combination With HX008 for Melanoma.

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: G-CSF After Chemo-radiation in Patients With Glioblastoma

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

New recruiting trial: CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer with Leptomeningeal Disease

A new clinical trial is recruiting patients for Isolated femoral agenesis/hypoplasia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Isolated femoral agenesis/hypoplasia

What is Isolated femoral agenesis/hypoplasia?

Isolated femoral agenesis/hypoplasia (also known as isolated proximal femoral focal deficiency or isolated femoral deficiency) is a rare congenital limb malformation characterized by the partial or complete absence (agenesis) or underdevelopment (hypoplasia) of the femur (thighbone). The condition may affect one leg (unilateral) or both legs (bilateral), with unilateral involvement being more common. The term 'isolated' indicates that the femoral deficiency occurs without other major associated anomalies, distinguishing it from syndromic forms such as femoral hypoplasia–unusual facies syndrome

How is Isolated femoral agenesis/hypoplasia inherited?

Isolated femoral agenesis/hypoplasia follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Isolated femoral agenesis/hypoplasia typically begin?

Typical onset of Isolated femoral agenesis/hypoplasia is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Isolated femoral agenesis/hypoplasia?

11 specialists and care centers treating Isolated femoral agenesis/hypoplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.